NCT03839433

The Mannitol-Asthma-Ciclesonide-Study

Ciclesonide for the Treatment of Airway Hyperresponsiveness: The Mannitol-Asthma-Ciclesonide-Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Cantonal Hosptal, Baselland · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Response of a 4 weeks treatment with daily once 320 µg ciclesonide on airway hyperresponsiveness assessed with mannitol. Hypothesis: Treatment with inhaled ciclesonide reduces airway hyper-responsiveness in 80% of hyper-responsive patients compared to 20% only in the placebo group and the group without airway hyper-responsiveness.

Conditions

• Asthma, Bronchial

Interventions

Type	Name	Description
DRUG	Ciclesonide

Timeline

• Start date: 2007-06-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2019-02-15
• Last updated: 2019-07-25